ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 489,35
0,59%
Dow Jones
42 657,64
-0,11%
DAX
20 340,57
0,65%
Brent Oil
76,915
1,05%
Bitcoin
96 670,06
-5,49%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Exelixis Inc (EXEL)

  7. Exelixis Inc (EXEL) Actualités

EXEL

Exelixis (EXEL)

Exelixis Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EXEL
DateHeureSourceTitreSymboleSociété
06/01/202522h05Business WireExelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025NASDAQ:EXELExelixis Inc
24/12/202402h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
29/11/202419h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
27/11/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in DecemberNASDAQ:EXELExelixis Inc
26/11/202422h05Business WireExelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine TumorsNASDAQ:EXELExelixis Inc
07/11/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in NovemberNASDAQ:EXELExelixis Inc
29/10/202421h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EXELExelixis Inc
29/10/202421h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EXELExelixis Inc
29/10/202421h05Business WireExelixis Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
15/10/202422h05Business WireExelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024NASDAQ:EXELExelixis Inc
15/10/202419h57Business WireExelixis Announces Update on Second Patent Litigation Trial with MSN LaboratoriesNASDAQ:EXELExelixis Inc
14/10/202414h00Business WireExelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell CarcinomaNASDAQ:EXELExelixis Inc
09/10/202414h30PR Newswire (Canada)ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORSNASDAQ:EXELExelixis Inc
16/09/202414h45Business WireExelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of MedicineNASDAQ:EXELExelixis Inc
15/09/202414h45Business WireExelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024NASDAQ:EXELExelixis Inc
28/08/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in SeptemberNASDAQ:EXELExelixis Inc
06/08/202423h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EXELExelixis Inc
06/08/202422h05Business WireExelixis Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
06/08/202414h30Business WireExelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine TumorsNASDAQ:EXELExelixis Inc
23/07/202422h05Business WireExelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024NASDAQ:EXELExelixis Inc
28/05/202422h05Business WireExelixis to Present at the William Blair 44th Annual Growth Stock ConferenceNASDAQ:EXELExelixis Inc
20/05/202414h00Business WireExelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USANASDAQ:EXELExelixis Inc
08/05/202422h11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EXELExelixis Inc
07/05/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MayNASDAQ:EXELExelixis Inc
30/04/202422h05Business WireExelixis Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
16/04/202422h05Business WireExelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024NASDAQ:EXELExelixis Inc
27/02/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MarchNASDAQ:EXELExelixis Inc
13/02/202415h19Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EXELExelixis Inc
06/02/202422h49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EXELExelixis Inc
06/02/202422h05Business WireExelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
 Showing the most relevant articles for your search:NASDAQ:EXEL

Dernières Valeurs Consultées

USI
USTECH100
US Tech 100
EU
AI
Air Liquide
NASDAQ
GOOGL
Alphabet
EU
VIV
Vivendi
COIN
BTCUSD
Bitcoin
EU
PX4
SBF 120
NYSE
DIS
Walt Disney
FTSE
UKX
FTSE 100
EU
ML
Michelin
EU
VK
Vallourec
NYSE
KO
Coca Cola
EU
AF
Air FranceKLM
NASDAQ
MSFT
Microsoft
COIN
XRPUSD
Ripple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés